Analysis to identify alterations in the FMR1 gene, the cause of Fragile X Syndrome, is essential for accurate diagnosis. This analysis typically involves polymerase chain reaction (PCR) to amplify the CGG repeat region of the gene, followed by methods such as capillary electrophoresis to determine the number of CGG repeats. Results can classify individuals as having a normal number of repeats, a premutation, or a full mutation, each correlating with different risks and potential health outcomes.
Confirmation of a diagnosis is critical for guiding patient management, genetic counseling, and family planning. Identifying carriers allows for informed decisions regarding future reproduction and potential interventions to mitigate health risks. Furthermore, understanding the genetic status within a family can help identify other at-risk individuals, enabling proactive monitoring and support. Development and refinement of these methodologies have significantly improved diagnostic accuracy and accessibility, benefiting both individuals and families affected by this condition.